Department of Pharmacology, University of Pennsylvania, Philadelphia, PA, USA.
Nicotine Tob Res. 2011 Jan;13(1):41-6. doi: 10.1093/ntr/ntq206. Epub 2010 Nov 22.
Clinical and preclinical studies suggest that regulation of nicotinic acetylcholine receptors (nAChR) maybe involved in the etiology of withdrawal symptoms.
We evaluated heteromeric nAChR regulation via [³H]epibatidine binding following cessation of chronic nicotine or varenicline treatment. Animals were concurrently tested in the marble-burying test to evaluate treatment-related effects.
We found that both nicotine (18 mg/kg/day, free base) and varenicline (1.8 mg/kg/day) chronically administered for 14 days upregulated nAChRs significantly in the cortex, hippocampus, striatum, and thalamus. The duration of upregulation (up to 72 hr) was both drug and region specific. In addition to nAChR upregulation, chronic administration of both nicotine and varenicline had anxiolytic-like effects in the marble-burying test. This effect was maintained for 48 hr following cessation of varenicline but was absent 24 hr following cessation from nicotine. Additionally, marble-burying behavior positively correlated to the regulation of cortical nAChRs following cessation of either treatment.
Varenicline has been shown to be an efficacious smoking cessation aid, with a proposed mechanism of action that includes modulation of dopamine release in reward areas of the brain. Our studies show that varenicline elicits both anxiolytic effects in the marble-burying test as well as region- and time-specific receptor upregulation. These findings suggest receptor upregulation as a mechanism for its efficacy as a smoking cessation therapy.
临床前和临床研究表明,烟碱型乙酰胆碱受体(nAChR)的调节可能与戒断症状的病因有关。
我们通过停止慢性尼古丁或伐伦克林治疗后[³H]依匹巴特定结合来评估异源 nAChR 的调节。同时在埋珠试验中对动物进行测试,以评估治疗相关的影响。
我们发现,14 天内每天给予 18mg/kg(碱基)尼古丁和 1.8mg/kg 伐伦克林,均可显著上调皮质、海马、纹状体和丘脑的 nAChR。上调的持续时间(长达 72 小时)因药物和区域而异。除了 nAChR 的上调外,慢性给予尼古丁和伐伦克林均具有埋珠试验中的抗焦虑样作用。这种作用在停止伐伦克林后 48 小时内保持,但在停止尼古丁后 24 小时内消失。此外,埋珠行为与停止任何一种治疗后皮质 nAChR 的调节呈正相关。
伐伦克林已被证明是一种有效的戒烟辅助剂,其作用机制包括调节大脑奖励区域的多巴胺释放。我们的研究表明,伐伦克林在埋珠试验中产生抗焦虑作用以及区域和时间特异性受体上调。这些发现表明,受体上调是其作为戒烟治疗的疗效机制之一。